Management and control of hypertension and proteinuria in patients with advanced chronic kidney disease under nephrologist care or not: Data from the AVENIR study (AVantagE de la Néphroprotection dans l'Insuffisance Rénale)

Nephrology Dialysis Transplantation

Volumn 24, Issue 3, 2009, Pages 934-939

  Thilly, Nathalie ^a,c   Boini, Stéphanie ^a   Kessler, Michèle ^b   Briançon, Serge ^a   Frimat, Luc ^b  

^a INSERM   (France)

^b CHU NANCY BRABOIS   (France)

^c UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

Chronic kidney disease; Clinical practice guidelines; Hypertension; Nephrologist care; Proteinuria

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; RENIN ANGIOTENSIN ALDOSTERON SYSTEM INHIBITOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NEPHROLOGIST; PATIENT CARE; PRIORITY JOURNAL; PROTEINURIA; RENAL REPLACEMENT THERAPY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CHRONIC DISEASE; COHORT STUDIES; FEMALE; FRANCE; HUMANS; HYPERTENSION; KIDNEY DISEASES; MALE; MIDDLE AGED; NEPHROLOGY; PROTEINURIA; REFERRAL AND CONSULTATION; RENAL DIALYSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 60749093692     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn566     Document Type: Article

References (33)

1. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305
2. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation 2007; 116: 85-97
3. Buckalew VM Jr, Berg RL,Wang SR et al. Prevalence of hypertension in 1,795 subjects with chronic renal disease: the Modification of Diet in Renal Disease Study baseline cohort. Am J Kidney Dis 1996; 28: 811-821
4. Segura J, Campo C, Gil P et al. Development of chronic kidney disease and cardiovascular prognosis in essential hypertensive patients. J Am Soc Nephrol 2004; 15: 1616-1622
5. Vupputuri S, Batuman V, Muntner P et al. Effect of blood pressure on early decline in kidney function among hypertensive men. Hypertension 2003; 42: 1144-1149
6. Weinstock Brown W, Keane WF. Proteinuria and cardiovascular disease. Am J Kidney Dis 2001; 38(Suppl 1): S8-S13
7. Keane WF. Proteinuria: its clinical importance and role in progressive renal disease. Am J Kidney Dis 2000; 35(Suppl 1): S97-S105
8. Palmer BF. Proteinuria as a therapeutic target in patients with chronic kidney disease. Am J Nephrol 2007; 27: 287-293
9. Wright JT Jr, Bakris G, Greene T et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288: 2421-2431
10. Ravera M, Re M, Deferrari L et al. Importance of blood pressure control in chronic kidney disease. J Am Soc Nephrol 2006; 17(Suppl 2): S98-S103
11. Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43(Suppl 1): S1-S290
12. Agence Nationale d'Accréditation et d'Evaluation en Santé. Clinical practice guidelines. Treatment strategies to slow the progression of chronic renal failure in adults. ANAES, Paris, France, 2004, 1-13
13. Jafar TH, Stark PC, Schmid CH et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003; 139: 244-252
14. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869
15. Hou FF, Zhang X, Zhang GH et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med 2006; 354: 131-140
16. Minutolo R, De Nicola L, Zamboli P et al. Management of hypertension in patients with CKD: differences between primary and tertiary care settings. Am J Kidney Dis 2005; 46: 18-25
17. Hsu CY, Bates DW, Kuperman GJ et al. Blood pressure and angiotensin-converting enzyme inhibitor use in hypertensive patients with chronic renal insufficiency. Am J Hypertens 2001; 14: 1219-1225
18. Peralta CA, Hicks LS, Chertow GM et al. Control of hypertension in adults with chronic kidney disease in the United States. Hypertension 2005; 45: 1119-1124
19. Schwenger V, Ritz E. Audit of antihypertensive treatment in patients with renal failure. Nephrol Dial Transplant 1998; 13: 3091-3095
20. De Nicola L, Minutolo R, Chiodini P et al. Global approach to cardiovascular risk in chronic kidney disease: reality and opportunities for intervention. Kidney Int 2006; 69: 538-545
21. Bailie GR, Eisele G, Liu L et al. Patterns of medication use in RRI-CKD study: focus on medications with cardiovascular effects. Nephrol Dial Transplant 2005; 20: 1110-1115
22. Wauters JP, Lameire N, Davison A et al. Why patients with progressing kidney disease are referred late to the nephrologists: on causes and proposals for improvement. Nephrol Dial Transplant 2005; 20: 490-496
23. Arora P, Obrador GT, Ruthazer R et al. Prevalence, predictors, and consequences of late nephrology referral at a tertiary care center. J Am Soc Nephrol 1999; 10: 1281-1286
24. Kessler M, Frimat L, Panescu V et al. Impact of nephrology referral on early and midterm outcomes in ESRD: EPidémiologie de l'Insuffisance REnale chronique terminale en Lorraine (EPIREL): results of a 2-year, prospective community-based study. Am J Kidney Dis 2003; 42: 474-485
25. Stack AG. Impact of timing of nephrology referral and pre-ESRD care on mortality risk among new ESRD patients in the United States. Am J Kidney Dis 2003; 41: 310-318
26. Thilly N, Boini S, Kessler M et al. Chronic kidney disease: appropriateness of therapeutic management and associated factors in the AVENIR study (AVantagE de la Néphroprotection dans l'Insuffisance Rénale). J Eval Clin Pract ; (accepted for publication in January 2008)
27. Paoletti E, Bellino D, Amidone M et al. Relationship between arterial hypertension and renal damage in chronic kidney disease: insights from ABPM. J Nephrol 2006; 19: 778-782
28. Mitka M. Research probes details of poor adherence in antihypertensive drug therapy. JAMA 2007; 298: 2128
29. De Nicola L, Minutolo R, Bellizzi V et al. Achievement of target blood pressure levels in chronic kidney disease: a salty question? Am J Kidney Dis 2004; 43: 782-795
30. Roumie CL, Elasy TA, Greevy R et al. Improving blood pressure control through provider education, provider alerts, and patient education: a cluster randomized trial. Ann Intern Med 2006; 145: 165-175
31. Aranda P, Segura J, Ruilope LM et al. Long-term renoprotective effects of standard versus high doses of telmisartan in hypertensive nondiabetic nephropathies. Am J Kidney Dis 2005; 46: 1074-1079
32. Palmer BF. Supratherapeutic doses of angiotensin-receptor blockers to decrease proteinuria in patients with chronic kidney disease. Am J Nephrol 2008; 28: 381-390
33. Wolf G, Ritz E. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic kidney disease: pathophysiology and indications. Kidney Int 2005; 67: 799-812